Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms
D. P. Duarte, A. J. Lamontanara, G. La Sala, S. Jeong, Y.-K. Sohn, A. Panjkovich, S. Georgeon, T. Kukenshoner, M. J. Marcaida, F. Pojer, M. De Vivo, D. Svergun, H.-S. Kim, M. Dal Peraro, O. Hantschel
This study identifies the Btk SH2-kinase interface as critical for activation and shows that targeting it with a repebody inhibits B-cell neoplasms.
bioRxiv · Dec 10, 2019Cancer Biology